In a child with an erection lasting more than four hours, how should I evaluate and manage priapism, including history, physical exam, blood gas analysis, analgesia, aspiration, phenylephrine administration, and possible surgical shunting?

Pediatric Priapism: Emergency Evaluation and Management

Immediate Diagnostic Evaluation

Any child presenting with an erection lasting more than 4 hours requires immediate corporal blood gas analysis to differentiate ischemic from non-ischemic priapism, as this single test determines whether you are managing a true urological emergency or a condition that can be observed. 1, 2

Critical History Elements

• Duration of erection – tissue damage begins at 6 hours, risk of permanent erectile dysfunction rises sharply after 24 hours, and approaches 90% after 36–48 hours 1, 3
• Pain characteristics – severe pain with full rigidity indicates ischemic priapism; painless partial tumescence suggests non-ischemic priapism 1, 3
• Recent trauma – perineal, genital, or pelvic injury points toward arterio-cavernosal fistula causing non-ischemic priapism 3
• Medication exposure – intracavernosal agents, phosphodiesterase-5 inhibitors, antipsychotics, antidepressants 1
• Hematologic disease – sickle cell disease accounts for 65% of pediatric priapism; leukemia (especially chronic myeloid leukemia) accounts for 10% 3, 4
• Previous episodes – stuttering priapism is a recurrent variant of ischemic priapism requiring preventive strategies 1

Physical Examination Findings

• Corpora cavernosa – rigid and tender in ischemic priapism; partially tumescent and painless in non-ischemic priapism 1, 3
• Glans penis and corpus spongiosum – characteristically remain soft in both types of priapism 1, 3
• Abdomen – palpate for splenomegaly suggesting hematologic malignancy such as CML 3
• Perineum – examine for signs of trauma or hematoma 1

Mandatory Laboratory Testing

• Corporal blood gas analysis (perform immediately without delay):
  • Ischemic: PO₂ <30 mmHg, PCO₂ >60 mmHg, pH <7.25 1, 2, 3
  • Non-ischemic: PO₂ >90 mmHg, PCO₂ <40 mmHg, pH ≈7.40 1, 2, 3
• Complete blood count with differential – screen for leukemia or anemia 3
• Hemoglobin electrophoresis – identify sickle cell disease or trait 3
• Penile duplex Doppler ultrasound – use when blood gas results are equivocal; ischemic priapism shows minimal or absent cavernous arterial flow 3

---

Emergency Management of Ischemic Priapism

Intracavernosal phenylephrine (100–500 µg/mL) combined with corporal aspiration and saline irrigation is the definitive first-line therapy for ischemic priapism persisting >4 hours, with a maximum dose of 1,000 µg within the first hour. 1, 2

Duration-Based Treatment Algorithm

Time Since Onset	Intervention	Expected Success
<4 hours (post-intracavernosal injection)	Immediate phenylephrine injection if fully rigid; observation if partially rigid [1]	High likelihood of rapid detumescence [1]
4–24 hours	Phenylephrine + aspiration/irrigation [1,2]	43–81% success rate; reasonable chance of preserving erectile function [1]
24–36 hours	Continue phenylephrine + aspiration; if refractory, proceed to distal surgical shunting [1]	Increasing failure rate; risk of permanent dysfunction rises markedly [1]
>36 hours	Distal surgical shunting (Winter or Al-Ghorab) ± tunneling; discuss early penile prosthesis implantation [1]	Low probability of erectile recovery; permanent dysfunction highly likely [1]

Phenylephrine Administration Technique

• Concentration: 100–500 µg/mL 1, 2
• Maximum dose: 1,000 µg within the first hour 1, 2
• Concurrent aspiration: Evacuate hypoxic blood from corpora cavernosa using a large-bore needle (16–19 gauge) 1
• Saline irrigation: Flush corpora with normal saline to restore normal metabolism 1
• Monitoring: Continuous cardiovascular monitoring during phenylephrine administration 1

Second-Line Surgical Shunting (When Phenylephrine Fails)

• Distal shunting procedures (Winter percutaneous shunt, Al-Ghorab open shunt, or tunneling techniques) achieve 60–80% success in refractory cases 1, 3
• Timing: Proceed to surgery without delay if repeated phenylephrine injections fail 1

---

Management of Non-Ischemic Priapism

Non-ischemic priapism is not a urological emergency; observation for up to 4 weeks is appropriate, as spontaneous resolution occurs in up to 62% of cases. 1, 2

• Do not perform aspiration or sympathomimetic injection – these are ineffective and potentially harmful in non-ischemic priapism 1, 2
• If intervention becomes necessary: Selective arterial embolization using temporary absorbable materials is the treatment of choice 1, 2

---

Special Considerations: Sickle Cell Disease

Do not postpone urologic intervention to perform exchange transfusion in sickle cell patients; immediate intracavernosal phenylephrine with aspiration is required, with concurrent systemic sickle cell management. 1, 3

• Concurrent systemic therapy: Aggressive hydration, analgesia, and exchange transfusion to reduce HbS to <30% should accompany—but never replace—standard ischemic priapism treatment 1, 3
• Systemic sickle cell treatments alone resolve priapism in only 0–37% of patients 3
• Simple transfusion to raise hemoglobin to 9–10 g/dL may be considered before general anesthesia if operative shunting is anticipated 1

---

Special Considerations: Leukemia-Associated Priapism

Priapism occurs in 2.5–3.3% of boys with chronic myeloid leukemia and requires immediate cytoreduction alongside standard urologic treatment. 3

• Concurrent cytoreduction: Hydroxyurea, leukapheresis, or exchange transfusion should be performed alongside penile aspiration and phenylephrine injection 3
• Do not delay urologic intervention while awaiting hematologic results 3

---

Analgesia and Supportive Care

• Adequate analgesia is essential during evaluation and treatment, as ischemic priapism causes severe pain 1
• Cold compress may be applied during initial evaluation but should not delay definitive treatment 5
• Ketamine and caudal block may be considered in the operating room for refractory cases requiring surgical intervention 5

---

Critical Pitfalls to Avoid

• Delaying corporal blood gas analysis can lead to misdiagnosis and inappropriate therapy 1, 2
• Waiting beyond 4 hours to initiate treatment results in smooth muscle edema and progressive irreversible damage 1, 2
• Postponing urologist consultation – early involvement improves outcomes and should never be delayed 1
• Using epinephrine or norepinephrine – phenylephrine is the only recommended sympathomimetic due to cardiovascular safety concerns 1
• Attempting aspiration or sympathomimetics for non-ischemic priapism – these are ineffective and potentially harmful 1, 2
• Delaying urologic intervention for exchange transfusion in sickle cell patients – this adds >6 hours without proven benefit over standard treatment 1
• Assuming priapism in children is benign – it frequently signals serious underlying pathology such as leukemia or sickle cell disease 3, 4

---

Patient and Family Counseling

• Explain that the likelihood of permanent erectile dysfunction correlates directly with priapism duration – treatment within the first 24 hours offers the best chance of functional recovery 1
• Inform families that erections lasting >36 hours have a low probability of erectile function restoration and may ultimately require penile prosthesis implantation 1
• Advise that untreated ischemic priapism inevitably leads to permanent loss of erectile function, corporal fibrosis, and penile shortening 1
• For patients with stuttering priapism: Instruct them to seek immediate urologic evaluation for any episode lasting >4 hours 1

---

Prevention of Recurrent Ischemic Priapism (Stuttering Priapism)

• PDE5 inhibitors (tadalafil or sildenafil) are first-line preventative therapy, reducing frequency and duration with no negative side effects 2
• Alternative preventative options: Ketoconazole with prednisone, hydroxyurea (specifically for sickle cell disease patients), and home self-injection of phenylephrine on an as-needed basis 2
• Caution with hormonal agents: Therapies that suppress the hypothalamic-pituitary-gonadal axis (e.g., ketoconazole, cyproterone acetate) may impair sperm parameters and should be discussed thoroughly with families of boys of reproductive age 1